Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV

References

• Ciccullo A, Baldin G, Borghi V, et al. Overall tolerability of integrase inhibitors in clinical practice: results from a multicenter Italian cohort. AIDS Res Hum Retroviruses. 2021;37(1):4–10.
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Milinkovic A, Pereira B, et al. Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIV. AIDS. 2019;33(15):2439–2441.
   PubMed Web of Science ®Google Scholar
• Pereira B, Mazzitelli M, Milinkovic A, et al. Evaluation of a clinic dedicated to people aging with HIV at Chelsea and Westminster Hospital: results of a 10-year experience. AIDS Res Hum Retroviruses. 2022;38(3):188–197.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21(1):4–10.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Brinson CC, Smith GHR, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-I adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15(10):1145–1155.
   PubMed Web of Science ®Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
   PubMed Web of Science ®Google Scholar
• Jaeger H, Overton ET, Richmond G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021;8(11):e679–e689.
   PubMed Web of Science ®Google Scholar
• Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–545.
   PubMed Web of Science ®Google Scholar
• Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307.
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF, 3rd, Monk TH, et al. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
   PubMed Web of Science ®Google Scholar
• Backhaus J, Junghanns K, Broocks A, et al. Test-retest reliability and validity of the Pittsburgh sleep quality index in primary insomnia. J Psychosom Res. 2002;53(3):737–740.
   PubMed Web of Science ®Google Scholar
• Curcio G, Tempesta D, Scarlata S, et al. Validity of the Italian version of the Pittsburgh sleep quality index (PSQI). Neurol Sci. 2013;34(4):511–519.
   PubMed Web of Science ®Google Scholar
• Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999;131(7):485–491.
   PubMed Web of Science ®Google Scholar
• WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization; 2024. [Accessed 2024 February 29]. Available at: https://www.who.int/publications/i/item/9789240015128.
   Google Scholar
• World Health Organization. Health topics/Alcohol. 2024. [Accessed 2024 February 29]. Available at: https://www.who.int/health-topics/alcohol.
   Google Scholar
• Beezer J, Al Hatrushi M, Husband A, et al. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2022;27(2):465–492.
   PubMed Web of Science ®Google Scholar
• Johnston MC, Crilly M, Black C, et al. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 2019;29(1):182–189.
   PubMed Web of Science ®Google Scholar
• Wu J, Wu H, Lu C, et al. Self-reported sleep disturbances in HIV-infected people: a meta-analysis of prevalence and moderators. Sleep Med. 2015;16(8):901–907.
   PubMed Web of Science ®Google Scholar
• Faraut B, Malmartel A, Ghosn J, et al. Sleep disturbance and total sleep time in persons living with HIV: a cross-sectional study. AIDS Behav. 2018;22(9):2877–2887.
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Trunfio M, Milinkovic A, et al. Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV. AIDS. 2023;37(6):925–934.
   PubMed Web of Science ®Google Scholar
• Duko B, Ayalew M, Ayano G. The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis. Subst Abuse Treat Prev Policy. 2019;14(1):52.
   PubMed Web of Science ®Google Scholar
• Wallace DR. HIV-associated neurotoxicity and cognitive decline: therapeutic implications. Pharmacol Ther. 2022;234:108047.
   PubMedGoogle Scholar
• Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf. 2013;12(6):841–846.
   PubMed Web of Science ®Google Scholar
• Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019;6(9):e576–e587.
   PubMed Web of Science ®Google Scholar
• Balthazar M, Diallo I, Pak VM. Metabolomics of sleep disorders in HIV: a narrative review. Sleep Breath. 2020;24(4):1333–1337.
   PubMed Web of Science ®Google Scholar
• Cabello-Ubeda A, Baeza AG, Toya Garcia G, et al. Changes in quality of sleep, mood, and other neuropsychiatric symptoms after switching dolutegravir/lamivudine/abacavir to darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a randomized study of people with human immunodeficiency virus with poor sleep quality: GESIDA 10418. Open Forum Infect Dis. 2022;9:ofac345.
   PubMed Web of Science ®Google Scholar